244 related articles for article (PubMed ID: 24821405)
1. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.
Hofford RS; Darna M; Wilmouth CE; Dwoskin LP; Bardo MT
Behav Brain Res; 2014 Aug; 270():151-8. PubMed ID: 24821405
[TBL] [Abstract][Full Text] [Related]
2. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.
Beckmann JS; Denehy ED; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Mar; 220(2):395-403. PubMed ID: 21938414
[TBL] [Abstract][Full Text] [Related]
3. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
[TBL] [Abstract][Full Text] [Related]
4. Reinstatement of methamphetamine conditioned place preference in nicotine-sensitized rats.
Berry JN; Neugebauer NM; Bardo MT
Behav Brain Res; 2012 Dec; 235(2):158-65. PubMed ID: 22884606
[TBL] [Abstract][Full Text] [Related]
5. Oxytocin treatment in the prelimbic cortex reduces relapse to methamphetamine-seeking and is associated with reduced activity in the rostral nucleus accumbens core.
Everett N; Baracz S; Cornish J
Pharmacol Biochem Behav; 2019 Aug; 183():64-71. PubMed ID: 31202809
[TBL] [Abstract][Full Text] [Related]
6. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats.
Alvers KM; Beckmann JS; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Psychopharmacology (Berl); 2012 Nov; 224(2):255-62. PubMed ID: 22638813
[TBL] [Abstract][Full Text] [Related]
7. PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.
Higley AE; Spiller K; Grundt P; Newman AH; Kiefer SW; Xi ZX; Gardner EL
J Psychopharmacol; 2011 Feb; 25(2):263-73. PubMed ID: 20142301
[TBL] [Abstract][Full Text] [Related]
8. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of naltrexone on relapse in methamphetamine self-administration and conditioned place preference in rats.
Guo LK; Wang ZY; Lu GY; Wu N; Dong GM; Ma CM; Zhang RL; Song R; Li J
Eur J Pharmacol; 2019 Dec; 865():172671. PubMed ID: 31542477
[TBL] [Abstract][Full Text] [Related]
10. Roles of levo-tetrahydropalmatine in modulating methamphetamine reward behavior.
Su HL; Zhu J; Chen YJ; Zhao N; Han W; Dang YH; Xu M; Chen T
Physiol Behav; 2013 Jun; 118():195-200. PubMed ID: 23711566
[TBL] [Abstract][Full Text] [Related]
11. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.
Wilmouth CE; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
Pharmacol Biochem Behav; 2013 Nov; 112():29-33. PubMed ID: 24075974
[TBL] [Abstract][Full Text] [Related]
13. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
[TBL] [Abstract][Full Text] [Related]
14. Administration of activated glial condition medium in the nucleus accumbens extended extinction and intensified reinstatement of methamphetamine-induced conditioned place preference.
Arezoomandan R; Moradi M; Attarzadeh-Yazdi G; Tomaz C; Haghparast A
Brain Res Bull; 2016 Jul; 125():106-16. PubMed ID: 27346277
[TBL] [Abstract][Full Text] [Related]
15. Effects of environmental enrichment on reinstatement of methamphetamine-induced conditioned place preference.
Althobaiti YS; Almalki AH
Behav Brain Res; 2020 Feb; 379():112372. PubMed ID: 31759048
[TBL] [Abstract][Full Text] [Related]
16. Effect of a 5-HT
Shahidi S; Komaki A; Sadeghian R; Soleimani Asl S
Brain Res; 2018 Nov; 1698():151-160. PubMed ID: 30076792
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
[TBL] [Abstract][Full Text] [Related]
18. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.
Eyerman DJ; Yamamoto BK
J Neurochem; 2007 Nov; 103(3):1219-27. PubMed ID: 17683483
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration.
Kufahl PR; Watterson LR; Nemirovsky NE; Hood LE; Villa A; Halstengard C; Zautra N; Olive MF
Neuropharmacology; 2013 Mar; 66():290-301. PubMed ID: 22659409
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward.
Anggadiredja K; Sakimura K; Hiranita T; Yamamoto T
Brain Res; 2004 Sep; 1021(2):272-6. PubMed ID: 15342276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
